Open AccessCabergoline treatment in prolactinoma: Amelioration in obstructive and central sleep apneas
Author(s) -
Murat Bınar,
Ömer Karakoç,
Cem Haymana,
Hasan Hüseyin Arslan
Publication year - 2019
Publication title -
journal of postgraduate medicine/journal of postgraduate medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.405
H-Index - 52
eISSN - 0972-2823
pISSN - 0022-3859
DOI - 10.4103/jpgm.jpgm_113_18
Subject(s) - medicine , cabergoline , obstructive sleep apnea , polysomnography , prolactinoma , excessive daytime sleepiness , anesthesia , central sleep apnea , apnea , pediatrics , sleep disorder , insomnia , prolactin , psychiatry , hormone
A 44-year-old male patient was admitted to the otolaryngology department with a history of progressive snoring, excessive daytime sleepiness, and reduced libido for the last 6 months. Polysomnography demonstrated the presence of moderate obstructive sleep apnea (OSA) with an apnea-hypopnea index (AHI) of 24.6 events/h, consisting of 77 obstructive and 59 central apneas. The marked number of central apneas in the sleep study and urologic complaints prompted the performance of brain magnetic resonance imaging (MRI), which indicated a pituitary macroadenoma (prolactinoma). Three months after treatment with cabergoline, a control MRI showed a significant reduction in the size of the macroadenoma. The AHI was also significantly decreased (to 11.6 events/h), as were the numbers of obstructive and central apneas. The patient's complaints regarding libido were also regressed. During this treatment period, CPAP therapy has not been tolerated by the patient. Cabergoline treatment reduced the severity of both obstructive and central sleep apneas in this patient.